You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Details for Patent: 8,012,976


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,012,976 protect, and when does it expire?

Patent 8,012,976 protects TALZENNA and is included in two NDAs.

This patent has fifty-five patent family members in thirty-one countries.

Summary for Patent: 8,012,976
Patent landscape, scope, and claims:
Title:Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Abstract: A compound having the structure set forth in Formula (I) and Formula (II): ##STR00001## wherein the substituents Y, Z, A, B, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
Inventor(s): Wang; Bing (San Jose, CA), Chu; Daniel (Santa Clara, CA)
Assignee: BioMarin Pharmaceutical Inc. (Novato, CA)
Application Number:12/510,096
Patent Claim Types:
see list of patent claims
Composition; Compound;

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,012,976

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer TALZENNA talazoparib tosylate CAPSULE;ORAL 211651-005 Jun 20, 2023 RX Yes No 8,012,976 ⤷  Subscribe Y Y ⤷  Subscribe
Pfizer TALZENNA talazoparib tosylate CAPSULE;ORAL 217439-001 Mar 7, 2024 RX Yes No 8,012,976 ⤷  Subscribe Y Y ⤷  Subscribe
Pfizer TALZENNA talazoparib tosylate CAPSULE;ORAL 211651-001 Oct 16, 2018 RX Yes No 8,012,976 ⤷  Subscribe Y Y ⤷  Subscribe
Pfizer TALZENNA talazoparib tosylate CAPSULE;ORAL 217439-002 Mar 7, 2024 RX Yes No 8,012,976 ⤷  Subscribe Y Y ⤷  Subscribe
Pfizer TALZENNA talazoparib tosylate CAPSULE;ORAL 211651-006 Jun 20, 2023 RX Yes No 8,012,976 ⤷  Subscribe Y Y ⤷  Subscribe
Pfizer TALZENNA talazoparib tosylate CAPSULE;ORAL 217439-003 Mar 7, 2024 RX Yes No 8,012,976 ⤷  Subscribe Y Y ⤷  Subscribe
Pfizer TALZENNA talazoparib tosylate CAPSULE;ORAL 211651-003 Sep 20, 2021 RX Yes No 8,012,976 ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,012,976

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2767537 ⤷  Subscribe CA 2019 00055 Denmark ⤷  Subscribe
European Patent Office 2767537 ⤷  Subscribe 301021 Netherlands ⤷  Subscribe
European Patent Office 2767537 ⤷  Subscribe PA2019522 Lithuania ⤷  Subscribe
European Patent Office 2767537 ⤷  Subscribe LUC00140 Luxembourg ⤷  Subscribe
European Patent Office 2767537 ⤷  Subscribe 2019C/551 Belgium ⤷  Subscribe
European Patent Office 2767537 ⤷  Subscribe 122019000108 Germany ⤷  Subscribe
European Patent Office 2767537 ⤷  Subscribe 1990055-4 Sweden ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.